The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review
复制标题
DOI：
10.1080/09513590.2017.1421632
复制
发表时间：
2018-01-01
影响因子：
2
通讯作者：
Kamenov, Zdravko
中科院分区：
文献类型：
--
作者：
Gateva, Antoaneta;Unfer, Vittorio;Kamenov, Zdravko
本文综述了肌醇在多囊卵巢综合征（PCOS）妇女的治疗和妊娠期糖尿病（GDM）的预防和治疗中的作用。我们以多囊卵巢综合征、肌醇、D-手性肌醇、辅助生殖技术和GDM为关键词对现有文献进行分析。最近的文献表明，肌醇，D-手性肌醇和它们的生理比例为40：1的组合可以代表一个重要的治疗策略，用于改善PCOS的代谢，激素和生殖方面。然而，在辅助生殖技术中，尽管D-手性肌醇单药治疗，但肌醇和联合治疗能够改善临床结果。肌醇单药治疗在预防和治疗GDM方面更有效，即使需要更大的研究队列来更好地阐明这些结果。
The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM). We analyzed the available literature with key words PCOS, Myo-inositol, D-chiro-inositol, assisted reproductive technologies and GDM. The most recent literature would suggest that Myo-inositol, D-chiro-inositol and their combination in physiological ratio 40:1 could represent an important therapeutic strategy for the improvement of metabolic, hormonal and reproductive aspects of PCOS. In assisted reproductive technologies, however, myo-inositol and the combined treatment, despite D-chiro-inositol monotherapy, are able to improve clinical outcomes. Myo-inositol monotherapy results more effective in preventing and treating GDM even if a larger cohort of studies is needed to better clarify these results.